This is a working overview of analytical methods, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
The basic principles of the biosynthesis of lactobacillic acid were already clarified in 1961. Lactobacillic acid, as well as other naturally occurring cyclopropane fatty acids (also abbreviated as CFA or CPFA) are formed from the corresponding unsaturated fatty acids, which have one carbon atom less, and have a cis configuration on the cyclopropane ring. The precursor of lactobacillic acid (cis-11,12-methylenoctadecanoic acid) is thus cis-vaccenic acid (cis-11-octadecenoic acid). This was demonstrated by carbon isotope14C labeled precursors. With the help of the enzymes cyclopropane fatty acid synthase, a methylene group is added to the double bond of cis-vaccenic acid. The methylene group originates from S-adenosylmethionine. The unsaturated fatty acid is not free, but is bound as an ester within phospholipids. The reaction mechanism proceeds via the formation of a carbocation. The enzyme catalyzes the reaction only with unsaturated fatty acids whose double bond has a cis configuration; the corresponding trans isomers are not converted. When the bacteria are cultivated in a batch culture, the formation of CFA occurs suddenly at a certain point in time rather than steadily increasing in concentration. At the same time, a decrease in the concentration of the unsaturated fatty acid (as a precursor) is observed. The formation of cyclopropane fatty acid occurs at the end of the exponential phase of growth or in the early stationary growth phase.
== Early life == Vincent Marks was born on 10 June 1930, in Harlesden, North West London, to Lewis and Rose (née Goldbaum) Marks, in a Jewish household. His parents ran a pub. Marks attended Tottenham Grammar School before going to study medicine on a scholarship at Brasenose College, Oxford, in 1948. He completed his training and qualified as a doctor from the St Thomas' Hospital in London, in 1954. It is noted that his interest in medicine was driven in part by his mother's insistence that their childhood home be neat and tidy for the "doctor's visit", leading him and his brother to think highly of doctors and medicine as a profession. During his time at Oxford, he was branded a communist after demanding that The Daily Worker, a newspaper mouthpiece of Communist Party of Great Britain, be introduced in the university's common rooms. He later joined the party, but left it in 1956 following the suppression of the Hungarian Uprising by the Soviet Union. In the 1980s he was a member of the Social Democratic Party (SDP).
== Allergy == Vicilins are a significant class of allergen found in legumes. The IgE binding proteins found were closely related and belonged to the 7S globulin family of seed storage proteins, which helped identify the allergen. Cross-reactions with various legumes are common when Pis s 1 and vicilins are combined in other seeds.
Sources: en.wikipedia.org
==== Assisted death in Canada ==== A lethal dose of propofol is used for medical assistance in dying in Canada to induce deep coma and death quickly, but rocuronium is always given as a paralytic, ensuring death, even when the patient has died as a result of an initial propofol overdose.
== Commemoration == In November 1927, Thomson opened the Thomson building, named in his honour, in the Leys School, Cambridge. In 1991, the thomson (symbol: Th) was proposed as a unit to measure mass-to-charge ratio in mass spectrometry in his honour. J J Thomson Avenue, on the University of Cambridge's West Cambridge site, is named after Thomson. The Thomson Medal Award, sponsored by the International Mass Spectrometry Foundation, is named after Thomson. The Institute of Physics Joseph Thomson Medal and Prize is named after Thomson. Thomson Crescent in Deep River, Ontario, connects with Rutherford Ave.
=== Current fleet === As of October 2026, 2GO and its subsidiaries own and operate a fleet of ten operating vessels, consisting of nine RoRo/Pax vessels and one freighter. 2GO's operating vessel fleet has a combined gross tonnage of approximately 159,295. Currently, 2GO operates seven large RoRo/Pax vessels calling on Manila as their homeport. These vessels sail from Luzon to Visayas and Mindanao. Furthermore, 2GO operates two medium-sized vessels with Batangas as their homeport, plying on the Batangas-Odiongan-Caticlan and the Batangas-Caticlan-Roxas routes. 2GO also operates one purely-cargo vessel, with Manila as its homeport, to complement its freight business. The company's flagship is currently the MV 2GO Masagana, one of the largest vessels ever to sail in the Philippines. 2GO's fleet includes two series of ships:
Soybean meal is a high protein source for fish and has become a substitute for traditionally used marine animal meals. Spirulina is a blue-green Cyanobacteria rich in raw protein, vitamins A, B1, B2, B6, B12, C and E, beta-carotene, color enhancing pigments, a whole range of minerals, essential fatty acids and eight amino acids required for complete nutrition. Whole wheat (carbohydrates) is not the best source of energy in fish but is an excellent source of roughage for fish such as Goldfish and Koi. It is also a natural source of vitamin E which promotes growth and enhances coloration.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.